

# A randomised, placebo-controlled study of nebulised magnesium in acute severe asthma in children

<b>Submission date</b> 05/11/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 15/11/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 24/07/2019	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Asthma is a common long-term condition that can cause coughing, wheezing, chest tightness and breathlessness. There is uncertainty in the management of acute asthma, with major differences between the management of children and adults. Adults are given magnesium intravenously (into a vein) early in the treatment of an acute asthma attack, but this is not recommended in children. Although magnesium is very safe when given intravenously, there is a need to monitor blood levels. A recent study in adults has demonstrated a good effect for magnesium given via a nebuliser (a machine that delivers medication by turning it into a mist to be inhaled through a face mask or mouthpiece). The aim of this study is to determine whether nebulised magnesium is useful in the treatment of acute asthma in childhood. Currently, the next step in the guidelines would be to commence intravenous treatment with medication to dilate (open up) the airways. If children respond to nebulised magnesium at this stage they may not need to go on to have a canula (needle) placed in the vein for more intensive treatment.

### Who can participate?

Children aged 2-16 with severe acute asthma

### What does the study involve?

When the child attends either a hospital emergency department or an emergency paediatric unit, if they do not respond to the standard treatment in the first 20 minutes, then they are randomly allocated to receive nebulised salbutamol and ipratropium bromide mixed with either magnesium sulphate or saline (dummy drug) on three occasions at 20-minute intervals. They are closely monitored over the following four hours.

### What are the possible benefits and risks of participating?

There are few side effects from magnesium, none described for inhaled magnesium, but these will be monitored by an independent committee.

### Where is the study run from?

University Hospital of Wales (UK)

When is the study starting and how long is it expected to run for?  
December 2007 to November 2010

Who is funding the study?  
Health Technology Assessment Programme (UK)

Who is the main contact?  
Dr Colin Powell  
colin.powell@cardiffandvale.wales.nhs.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Colin Powell

**Contact details**  
Department of Paediatrics  
University Hospital of Wales  
Heath Park  
Cardiff  
United Kingdom  
CF14 4XW  
+44 (0)29 2074 7747  
colin.powell@cardiffandvale.wales.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
HTA 05/503/10

## Study information

**Scientific Title**  
A randomised, placebo-controlled study of nebulised magnesium in acute severe asthma in children

**Acronym**  
MAGNETIC

**Study objectives**

Does nebulised magnesium used as an adjunct to nebulised salbutamol and ipratropium bromide for one hour in children with severe asthma result in a clinical improvement when compared to nebulised salbutamol, ipratropium bromide and placebo?

More details can be found at: <http://www.nets.nihr.ac.uk/projects/hta/0550310>

Protocol can be found at: [http://www.nets.nihr.ac.uk/\\_\\_data/assets/pdf\\_file/0017/51218/PRO-05-503-10.pdf](http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0017/51218/PRO-05-503-10.pdf)

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

North West Research Ethics Committee, 18/02/2008, ref: 07/H1010/101

### **Study design**

Multicentre randomised placebo-controlled study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Severe exacerbation of asthma

### **Interventions**

Children aged 2 - 5 years will be randomised to receive nebulised salbutamol 2.5 mg and ipratropium bromide 0.25 mg mixed with either 2.5 ml of isotonic magnesium sulphate (250 mmol/L, tonicity 289 mOsm; 151 mg per dose) or 2.5 ml of isotonic saline on three occasions at twenty-minute intervals. Children 6 years and over will receive 5 mg of nebulised salbutamol.

Total duration of follow-up is one month.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Magnesium, salbutamol, ipratropium bromide

### **Primary outcome measure**

The Yung Asthma Severity Score (ASS) after 60 minutes of treatment

### **Secondary outcome measures**

Clinical (during hospitalisation):

1. Stepping down of treatment at one hour i.e. changed to having hourly treatment after the initial three, twenty-minute nebulisers
2. Number and frequency of additional salbutamol
3. Length of stay in hospital
4. Requirement for intravenous bronchodilator treatment
5. Intubation and/or admission to a Paediatric Intensive Care Unit (PICU)

Patient outcomes at follow-up (1 month):

1. Paediatric Quality of Life Inventory (PedsQL™) asthma module parental report for all children and self-completion if aged over 5 years, European Quality of Life questionnaire (EQ-5D)
2. Time off school/nursery
3. Health care resource usage (e.g. General Practitioner [GP] visits, additional prescribing)

Parent outcomes at follow-up (1 month):

1. Time off work (related to child's illness)

### **Overall study start date**

01/12/2007

### **Completion date**

25/10/2011

## **Eligibility**

### **Key inclusion criteria**

For children 6 years and older severe asthma is based on at least one of the following criteria being met:

1. Oxygen saturations less than 92% while breathing room air
2. Too breathless to talk
3. Heart rate greater than 120/min
4. Respiratory rate greater than 30/min
5. Use of accessory neck muscles

For children aged 2 - 5 years of age, severe asthma is based on at least one of the following criteria being met:

1. Oxygen saturations less than 92% while breathing room air
2. Too breathless to talk
3. Heart rate greater than 130/min
4. Respiratory rate greater than 50/min
5. Use of accessory neck muscles

### **Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

6 Years

**Sex**

Both

**Target number of participants**

500

**Key exclusion criteria**

1. Coexisting respiratory disease such as cystic fibrosis, chronic lung disease of prematurity
2. Severe renal disease
3. Severe liver disease
4. Known to be pregnant
5. Known to have had a reaction to magnesium previously
6. Parents who are unable to give informed consent
7. Previously randomised into MAGNETIC trial
8. Patients who present with life threatening symptoms
9. Previously involved with a trial of a medicinal product in the three months preceding screening

**Date of first enrolment**

01/12/2007

**Date of final enrolment**

30/11/2010

**Locations****Countries of recruitment**

United Kingdom

Wales

**Study participating centre**

University Hospital of Wales

Cardiff

United Kingdom

CF14 4XW

**Sponsor information****Organisation**

Cardiff University (UK)

**Sponsor details**

Newport Road  
Cardiff  
Wales  
United Kingdom  
CF24 0DE  
+44 (0)29 2087 9274  
davieskp2@cardiff.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.cf.ac.uk>

**ROR**

<https://ror.org/03kk7td41>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Health Technology Assessment Programme

**Alternative Name(s)**

NIHR Health Technology Assessment Programme, HTA

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2013		Yes	No
<a href="#">Results article</a>	results	01/10/2013		Yes	No
<a href="#">Results article</a>	results	23/12/2016		Yes	No